GLP-1 Medications and Testosterone: The 2026 Research Update

Updated March 2026 • 11 min read • Research analysis

The GLP-1 → Testosterone Connection: A Quick Recap

If you haven't read our foundational article on GLP-1 and testosterone, here's the essential background: excess body fat actively suppresses testosterone production in men through a well-documented biochemical cascade.

Adipose tissue (fat) contains the enzyme aromatase, which converts testosterone into estradiol (a form of estrogen). The more fat you carry, the more aromatase activity you have, and the more of your testosterone gets converted to estrogen. This creates a self-reinforcing loop — low testosterone makes it harder to build muscle and easier to store fat, which creates more aromatase, which converts more testosterone, which makes you fatter.

GLP-1 medications break this cycle by producing significant weight loss. As fat mass decreases, aromatase activity drops, testosterone conversion slows, and free testosterone levels begin to recover. The question has always been: how much recovery, and is it enough to meaningfully change a man's hormonal health?

The 2025–2026 research data is providing increasingly clear answers.

ENDO 2025 Data: The Landmark 77% Finding

Data presented at the Endocrine Society's ENDO 2025 annual meeting represented the most robust evidence yet that GLP-1-mediated weight loss reliably restores testosterone in men. The analysis pooled data from multiple GLP-1 trials and found that among men who entered treatment with testosterone levels below 300 ng/dL (the clinical threshold for hypogonadism) and achieved at least 10% body weight reduction:

77% reached testosterone levels at or above 300 ng/dL — the standard clinical threshold for normal male testosterone. The mean testosterone increase was approximately 120–180 ng/dL, with some men seeing increases of 200+ ng/dL. The testosterone recovery correlated directly with the magnitude of weight loss — men who lost 15%+ of body weight saw larger testosterone gains than men who lost 10–15%.

This has direct clinical implications. For the millions of men who've been diagnosed with "low T" and started testosterone replacement therapy (TRT), the question now is: how many of them had obesity-related low testosterone that could have been corrected with weight loss instead?

Mendelian Randomization Studies: From Correlation to Causation

One of the most important methodological advances in 2025–2026 GLP-1 research has been the application of Mendelian randomization (MR) to the weight-testosterone relationship. MR uses genetic variants as "natural experiments" to establish causal relationships, avoiding the confounding issues that plague observational studies.

Multiple MR analyses published in 2025 reached the same conclusion: genetically predicted higher BMI causally reduces testosterone levels in men. Conversely, genetically predicted GLP-1 receptor activation is associated with both lower BMI and higher testosterone levels. This isn't just correlation — the genetic evidence demonstrates a causal pathway from GLP-1 receptor activation → weight loss → testosterone recovery.

The same MR methodology also strengthened the evidence for another GLP-1 benefit men care about: erectile function improvement. Genetically predicted GLP-1 receptor agonism was associated with reduced risk of erectile dysfunction, operating through both the weight loss → testosterone pathway and a direct vascular improvement pathway — read our full ED article for details.

Tirzepatide and Testosterone: Is the Dual Agonist Better?

Most of the testosterone-restoration research to date has focused on semaglutide, because semaglutide has been studied longer and in more trials. But tirzepatide's superior weight loss (20–22% vs 15–17%) raises an obvious question: does more weight loss mean more testosterone recovery?

The early data suggests yes, with a caveat. Because testosterone recovery correlates with total weight loss, and tirzepatide produces more total weight loss, men on tirzepatide can expect proportionally greater testosterone improvement — perhaps 20–30% more testosterone recovery compared to semaglutide at equivalent time points.

However, the relationship between weight loss and testosterone isn't perfectly linear. Most of the testosterone benefit comes from the first 10–15% of body weight loss, as this is where the majority of visceral fat reduction (and therefore aromatase reduction) occurs. Beyond 15% weight loss, testosterone gains continue but at a diminishing rate. A man who loses 20% of his body weight on tirzepatide won't have double the testosterone increase of a man who loses 10% on semaglutide — he might have 30–40% more.

The GIP receptor activation specific to tirzepatide may also provide independent metabolic benefits that affect testosterone, but this is still being studied. Some researchers hypothesize that GIP's effects on insulin signaling and adipose tissue metabolism could improve the hormonal environment beyond what weight loss alone explains. Watch for dedicated tirzepatide-testosterone data from the SURMOUNT long-term extension studies expected later in 2026.

Updated Mechanism: The Full Cascade

Based on 2025–2026 research, here's the current understanding of how GLP-1 medications restore testosterone in men:

The net result is a cascade of improvements that reinforce each other. No single mechanism accounts for all of the testosterone recovery — it's the cumulative effect of reduced aromatase, restored HPG signaling, improved insulin sensitivity, reduced inflammation, and better sleep quality that produces the 120–180 ng/dL average increase seen in clinical data.

Testosterone Recovery Timeline: What to Expect

Key caveat: these timelines assume consistent medication adherence and at least minimal lifestyle support (adequate protein, some resistance training). Men who combine GLP-1 therapy with structured exercise and protein-first nutrition tend to see faster and more robust testosterone recovery than those relying on medication alone.

GLP-1 vs TRT: Can GLP-1s Replace Testosterone Replacement?

This is the question men ask most, and the answer depends entirely on why your testosterone is low.

The practical implication: if you're an overweight man with low testosterone, GLP-1 therapy should be the first intervention — not TRT. Give it 6–12 months, monitor testosterone levels, and only add TRT if GLP-1-mediated weight loss fails to produce adequate hormonal recovery. This approach avoids the side effects, fertility implications, and lifetime dependency of testosterone replacement while addressing the underlying problem.

For men currently on both GLP-1 therapy and TRT, our GLP-1 + TRT combination article covers the protocols, monitoring, and when to consider tapering TRT as your natural testosterone recovers. For deep-dive TRT information, visit our partner site TrueTRT.co.

Lab Monitoring: What to Test and When

If testosterone recovery is one of your goals on GLP-1 therapy (and for most men, it should be — even if it wasn't your primary motivation for starting), here's the lab panel you should request:

Baseline (before starting GLP-1): Total testosterone, free testosterone, SHBG, estradiol, LH, FSH, prolactin, metabolic panel, lipid panel, A1C, fasting insulin. This establishes your starting point and identifies whether hypogonadism is primary (testicular) or secondary (pituitary/hypothalamic).

3-month follow-up: Total testosterone, free testosterone, estradiol. This is your early indicator — if testosterone is trending up even modestly, the mechanism is working.

6-month follow-up: Full panel repeat. This is your decision point — if testosterone has increased meaningfully (≥50 ng/dL), you're on track. If not, discuss TRT consideration with your provider.

12-month follow-up: Full panel repeat. This establishes your new hormonal baseline and determines long-term treatment strategy.

Several GLP-1 telehealth providers include lab work in their programs. MEDVi (see details) offers the most comprehensive lab monitoring among the providers we've evaluated.

What This Means for Your Treatment Plan

The 2026 research reinforces a message that was already becoming clear: for overweight men with low testosterone, GLP-1 therapy isn't just a weight loss treatment — it's a testosterone restoration treatment that happens to work through weight loss. The evidence base is now strong enough that this should change clinical practice.

If you're a man with a BMI above 27 and testosterone below 400 ng/dL, here's the evidence-based action plan: